Aim: Postprandial hypertriglyceridemia (PHTG) has been shown repeatedly to be associated with metabolic syndrome and atherosclerotic cardiovascular diseases. We have recently reported that ezetimibe inhibits PHTG in patients with type b hyperlipidemia. Ezetimibe was also reported to attenuate PHTG in combination with low-dose statins in patients with obesity or metabolic syndrome. We reported CD36-deficient (CD36KO) mice as a new model for PHTG, in which the synthesis of chylomicron (CM) in the small intestines is enhanced. In the current study, we investigated the effect of ezetimibe on PHTG in this mouse model of metabolic syndrome. Methods: Wild-type (WT) mice fed a western diet, and CD36KO mice fed a normal chow diet, respectively, were treated for 3 weeks with and without ezetimibe, followed by an evaluation of triglyceride (TG) concentrations by enzymatic method and by high performance liquid chromatography (HPLC) as well as those of and apolipoprotein (Apo) B-48 in plasma and intestinal lymph after oral fat loading with olive oil. Intestinal mucosa was also harvested to evaluate the transcriptional regulation of the genes involved in the intestinal production of ApoB-containing lipoproteins. Results: Ezetimibe dramatically reduced PHTG in both WT and CD36KO mice. HPLC analysis of plasma showed that the decrease in TG content in CM and CM remnants-sized particles contributed to this suppression, suggesting that CM production in the small intestines might be reduced after ezetimibe treatment. Intestinal lymph was collected after oral fat loading in ezetimibe-treated and non-treated mice. Both TG content and ApoB-48 mass were decreased in ezetimibe-treated mice. The quantitative RT-PCR of intestinal mucosa showed down-regulation of the mRNA expression of FATP4 and ApoB in both groups along with FABP2, DGAT1, DGAT2 and SCD1 in WT mice at postprandial state after ezetimibe treatment. Conclusion: Ezetimibe alone reduces PHTG by blocking both the absorption of cholesterol and the intracellular trafficking and metabolism of long-chain fatty acids in enterocytes, resulting in the reduction of the formation of ApoB-48 which is necessary for the ApoB48-containing lipoprotein production in the small intestines. 
Introduction
Metabolic syndrome (MetS) is defined as a cluster of interrelated factors commonly associated with atherosclerotic cardiovascular diseases: central obesity, modestly high blood pressure, impaired glucose metabolism and atherogenic dyslipidemia 1) , including elevated triglyceride (TG) in the fasting state.
Besides the early hours of the day before breakfast, we are constantly in a non-fasting state. Accumulating evidence concerning nonfasting TG levels as a predictor of cardiovascular diseases 2) and stroke 3) suggest atherosclerosis as a postprandial phenomenon in which intestine-derived TG-rich lipoproteins, such as chylomicron (CM) and CM remnants, would play an important role [4] [5] [6] , which Zilversmit stated three decades ago 7) . CD36, or fatty acid translocase, is an 88 kD scavenger receptor class B that is expressed in many cells, such as monocytes, macrophages, microvascular endothelial cells, adipocytes, skeletal and cardiac myocytes and enterocytes. It binds multiple ligands, including long-chain fatty acids (FAs) and oxidized low density lipoprotein 8) . Patients with CD36 deficiency present with increased remnant lipoproteins and decreased high density lipoprotein (HDL)-cholesterol, as well as impaired glucose metabolism based upon insulin resistance. All these findings suggest that CD36 deficiency may be considered a monogenic form of MetS 9) . CD36 knockout (CD36KO) mice present with an excessive postprandial plasma TG and FA response after acute oral fat loading compared to wild-type (WT) mice 10) . Previous studies in our laboratory using CD36KO mice reported a postprandial increase in plasma CM and CM remnants with enhanced TG synthesis in the small intestines, suggesting that the main cause of postprandial hypertriglyceridemia (PHTG) in CD36KO mice was the increased de novo synthesis of small CM in enterocytes 11) . These findings established CD36KO mice as a model to evaluate PHTG in a MetS environment.
Ezetimibe, a cholesterol absorption inhibitor that acts by blocking the sterol-induced internalization of the key cholesterol transporter, Niemann-Pick C1 Like 1 (NPC1L1), in enterocytes 12) has been demonstrated to lower total and LDL-cholesterol levels significantly in patients with primary and mixed hypercholesterolemia as a coadjuvant therapy to either statins 13) or fibrates 14) . In these studies, ezetimibe was also found to decrease other important atherogenic factors significantly, such as fasting TG and total apolipoprotein B (ApoB) levels in plasma. Moreover, ezetimibe has been demonstrated to reduce PHTG in combination with low-dose statins in patients with obesity and metabolic syndrome comparable to highdose statins alone 15) . Recently, our group reported that ezetimibe alone significantly reduced PHTG in Japanese subjects with type b hyperlipidemia 16) , suggesting that ezetimibe might also play a role in regulating the production of TG-rich lipoproteins in addition to act as a cholesterol absorption inhibitor. Since investigations concerning ezetimibe and its mechanism of action on lipid metabolism have primarily focused on sterol metabolism, we prioritized the need to establish molecular mechanisms that participate in the TG-lowering effect of ezetimibe in the postprandial state. For that purpose, we performed oral fat loading in ezetimibe-treated and nontreated wild-type (WT) mice fed a western diet and CD36KO mice fed a chow diet as an animal model of PHTG. We demonstrated that ezetimibe reduces PHTG by decreasing the absorption of both cholesterol and long-chain FAs through enterocytes, which affected intestinal FA transport, TG production, and CM formation in both mice strains.
Materials and Methods

Animals
Male C57BL6/J WT and CD36KO mice created on a C57BL6/J background (kindly provided by Mason. W. Freeman, M.D., Ph.D., Professor of Harvard Medical School) 17) , 8 − 10 weeks of age were used for this experiment. Each mouse strain was separated into two groups in the following manner: CD36KO mice were fed a chow diet (MF; Oriental BioLaboratories, Chiba, Japan) either with or without supplementation of 10 mg/kg ezetimibe (Schering-Plough, USA), and WT mice were fed a western diet either with or without supplementation of 10 mg/kg ezetimibe. The animals were housed in a temperature-controlled environment at 12-hour dark-light cycles with free access to food and water. After 3 weeks of treatment, mice in each group were divided into 2 subgroups. One subgroup was euthanized after fasting for 12 h and the other was fasted for 12 h followed by acute ingestion of 17 L/g body weight of olive oil (Nacalai Tesque, Kyoto, Japan) by intragastric gavage, and then euthanized 3 h after initiating oral fat loading. Plasma, intestinal lymph and tissues were collected from both subgroups at the time of euthanization. Additionally, WT mice fed a standard chow diet were used as controls for the TG determination study. The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Osaka University Graduate School of Medicine (IEXAS).
Lipid Determination and Lipoprotein Analysis of Plasma and Intestinal Lymph
Cholesterol and TG concentrations in plasma and intestinal lymph for each mouse were measured using an enzymatic method (Wako Pure Chemical Industries, Tokyo, Japan) according to the manufacturer's protocol. Plasma and lymph lipoprotein profiles were analyzed by an online dual enzymatic method using high performance liquid chromatography (HPLC) at Skylight Biotech Inc. (Akita, Japan) 18) . Two hundred microliters of plasma or lymph were dissolved in loading buffer and loaded onto TSK gel Lipopropak XL columns; TG concentrations in the flow-through were measured continuously and simultaneously. The correspondence of the size of lipoprotein fractions (CM, very low density lipoprotein (VLDL), LDL, and HDL-sized fractions) and the elution time were; CM (particle diameter 80 nm, elution time: 15 − 17 min), VLDL (particle diameter: 30 − 80 nm, elution time: 17 − 22 min), LDL (particle diameter: 16 − 30 nm, elution time: 22 − 28 min), and HDL (particle diameter: 8 − 16 nm, elution time: 28 − 37 min).
Collection of Intestinal Lymph in Postprandial State
Five mice from each group, previously fasted for 12 h, were gavaged with olive oil (17 L/g body weight). Three hours later, the animals were anesthetized and the intestinal lymphatic trunk was cannulated with a 27-gauge needle connected to a polyethylene tube (PE-50), which was pretreated with EDTAcontaining water. The procedure was performed in accordance with the modified method described by Bollman et al. 19) . The collected intestinal lymph was used for HPLC and protein detection by western blot.
Determination of Labeled Triolein Absorption
Mice from each group were fasted for 12 h and gavaged with 3 Ci of [9, H(N)] triolein (PerkinElmer, MA, USA) mixed into 17 L/g body weight of olive oil. Three hours after fat loading, the mice were euthanized and blood samples were collected from the inferior vena cava. The activity of radiolabeled tritium in 250 L plasma was determined by scintillation counting using a WALLAC Winspectral TM 1414 Liquid Scintillation Counter.
Protein Detection by Western Blot
One microliter of sample (plasma or lymph) was subjected to 4 − 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE; TEFCO, Tokyo, Japan), later transferred onto an Immobilon-P transfer membrane (Millipore Co., USA), and blocked by Blocking One (Nacalai Tesque, Kyoto, Japan). The blotted membrane was then incubated with anti-mouse ApoB-48/ B-100 antibody (BIODESIGN International, ME, USA) and anti-rabbit IgG as a secondary antibody (NA934V; GE Healthcare Backinghamshire, UK). Bands corresponding to ApoB-48 were detected with the ECL Advance Detection Kit (GE Healthcare, UK).
RNA Extraction, cDNA Synthesis and Quantitative Real-Time PCR
Mice were fasted for 12 h, gavaged with olive oil as previously stated, and their small intestines were removed, flushed with ice-cold phosphate-buffered saline and divided into three sections of equal length; the proximal two-thirds of mucosa were gently scraped and stored in RNAlater RNA stabilization reagent (QIAGEN GmbH, Germany) at 20 .
Total RNA from tissue samples were extracted and purified using the RNeasy Plus Mini Kit (cat. 74134; QIAGEN GmbH, Germany). Two micrograms of total RNA were primed with 50 pmol anchored-oligo (dT)18 and transcribed with the Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, Germany), according to the manufacturer's protocol. Quantitative RT-PCR was performed; DNA polymerase and SYBR Green I (Finnzymes Oy, Espoo, Finland) were set in a reaction volume of 20 L containing gene-specific primers (5 M) and cDNA (corresponding to ~50 ng total RNA). The reaction was performed using the DNA engine Opticon 2 real-time PCR detection system (Bio-Rad Laboratories, Hercules, CA). The 2 CT method of relative gene expression was employed and standard deviation with a ct value of 0.3 was accepted. Results are expressed as arbitrary units in comparison with the expression of GAPDH.
Primers Used for This Study
The sequence data of the genes were found with GenBank and the sequences of primers were designed with Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/ primer3_www.cgi). GAPDH was used as a housekeeping gene. The sequence and information for primers 
Statistical Analysis
The values were expressed as the means S.D. Statistical significance was assessed by Student's t -test for paired values and set at p 0.05.
Results
Ezetimibe Reduces Postprandial Hypertriglyceridemia in Both CD36KO and Wild Type Mice
CD36KO mice fed a standard chow diet and WT mice fed a western diet showed significantly higher plasma TG levels than WT fed a standard chow diet in the postprandial state without ezetimibe treatment (CD36KO 457 114 mg/dL, WT western diet 376 41 mg/dL vs WT chow diet 267 81 mg/dL. n 25). Administration of ezetimibe decreased plasma TG concentrations in the postprandial state in both CD36KO and WT fed a western diet but not in WT mice fed a standard chow diet (Fig. 1A) as well as plasma total cholesterol concentrations in plasma in both study groups (Fig. 1B) . The selective decrease in both postprandial TG levels suggests that the ezetimibe action on plasma TG concentrations is enhanced by a postprandial MetS environment, since both affected groups are indeed animal models of postprandial hyperlipidemia.
Ezetimibe Reduces Postprandial CM and VLDLSized Particles as Well as ApoB48 Mass in Plasma of WT and CD36KO Mice
Plasma lipoprotein profile was analyzed by HPLC using five samples for each group. The highest peak corresponded to CM-and VLDL-sized fractions in both ezetimibe-treated and non-treated mice in both groups. We found that ezetimibe reduced postprandial TG levels in both WT and CD36KO mice mainly in CM-and VLDL-sized subfractions, which corresponded to CM remnants ( Fig. 2A and 2B) . Moreover, ezetimibe decreased the ApoB48 mass in plasma in both groups. These results support the idea that ezetimibe might have some modulating effect on intestinal CM production. Thus, we further investigated lipoproteins in the intestinal lymph, the intestinal absorption of tritium-labeled FAs, and intestinal mRNA expression of a variety of genes involved in CM synthesis in both strains of mice in the postpran- Plasma lipoprotein profile was analyzed by HPLC. Ezetimibe (dotted line) reduced the average postprandial TG levels in both CD36KO (A) and WT mice (B) in CM-and VLDL-sized subfractions, which corresponded to CM remnants. Moreover, ezetimibe decreased the ApoB48 mass in plasma in both groups (representative sample). These results support the idea that ezetimibe might have some modulating effect on intestinal CM production. 
Ezetimibe Reduces Postprandial TG and ApoB48
Mass in Intestinal Lymph of WT and CD36KO Mice Ezetimibe reduced the postprandial TG concentration significantly in intestinal lymph of both study groups in the postprandial state; this reduction was accompanied by a decrease in apoB48 mass in lymph. The highest peak in TG levels corresponded to the CM fraction in treated and non-treated mice in both groups. Ezetimibe decreased the CM peak, suggesting that it might act by lowering the production of intestine-derived lipoproteins in the postprandial state in both groups of mice (Fig. 3A and 3B) .
Ezetimibe Reduces the Intestinal Absorption of Radio-Labeled Triolein
To investigate the possible mechanisms by which ezetimibe reduced the intestinal TG secretion, we evaluated intestinal FA absorption. Ezetimibe-treated and non-treated mice from both strains were loaded with 17 L/g olive oil containing 3 Ci of [9, H(N)] triolein. At 3 h after oral fat loading, ezetimibe significantly reduced 3 H radioactivity in the plasma of both strains ( Fig. 4A and 4B) , establishing that there is a reduction in intestinal FA absorption associated with the administration of ezetimibe. HPLC analysis showed that ezetimibe (dotted lines) reduced significantly the average postprandial TG concentration in the intestinal lymph of CD36KO (A) and WT (B) mice in the postprandial state; this reduction was accompanied by a decrease in ApoB48 mass. Ezetimibe decreased the CM peak in both groups, suggesting that it might act by lowering the production of intestine-derived lipoproteins in the postprandial state. 
Effect of Ezetimibe on the Transcriptional Regulation of Genes Involved in Fatty Acid Transport, TG Formation and CM Assembly in the Intestinal Cells in the Postprandial State
To determine the molecular mechanisms involved in the attenuation of PHTG by ezetimibe, qRT-PCR using total mRNA isolated from the small intestines was performed, and the expression of genes associated with FA transport, TG formation and CM assembly in the intestine of both strains treated and non-treated with ezetimibe was examined.
In CD36KO mice, the mRNA levels of fatty acid transport protein 4 (FATP4), the only FATP in the intestine, were significantly reduced by the administration of ezetimibe, whereas the mRNA levels of fatty acid binding protein 1 (FABP1) and FABP-2, which are also associated with the transport of long-chain FAs, were not changed significantly in the treated groups. The mRNA expression of stearoyl-coenzyme A desaturase 1 (SCD1), diacyl glycerol acyl transferase 1 (DGAT1), DGAT-2, and monoacyl glycerol acyl transferase 2 (MGAT2), all involved in the intracellular formation of TG in intestinal epithelial cells, did not change significantly in the presence of ezetimibe. Interestingly, ApoB mRNA was found to be decreased in mice treated with ezetimibe; this reduction might be associated with a decrease in the expression of apobec-1 mRNA, one of the important factors and components of the protein complex involved in the mRNA edition of ApoB. The expression of microsome triglyceride transfer protein (MTP), which has an important role in CM assembly in intestinal cells, did not change significantly in the presence of ezetimibe. These results suggest that reduction in the hypertriglyceridemic response of ezetimibe in CD36KO mice might be associated with a decrease in cholesterol absorption, fatty acid transport and apo B48 synthesis, resulting in the attenuated formation of CM by a reduction of apoB48 mRNA (Fig. 5A) .
In WT mice fed a western diet, the mRNA levels of FATP4 and FABP2 were found to be reduced by the administration of ezetimibe, while FABP1 and CD36 were unaffected by this treatment; we also found that SCD1, DGAT1 and DGAT2 were decreased in treated mice. Moreover, in this group, we also found that apoB mRNA was decreased, and this reduction might be associated with a decrease in ACF (apobec-1 complementary factor), a component of the apoB mRNA editing complex. These results suggest that ezetimibe reduces PHTG in WT mice by decreasing fatty acid transport, TG formation and CM assembly in intestinal epithelial cells (Fig. 5B) .
We also identified an upregulation of fatty acid synthase (FAS), and acetyl-Coenzyme A acetyltransferase 2 (ACAT2) in both groups, which might be due to compensatory responses to the reduction of fatty acid transport and CM production.
Discussion
In the present study, we have investigated the inhibitory effect of ezetimibe on PHTG in MetS using two different animal models: WT mice fed a western, high fat, high cholesterol diet; and CD36KO mice, which is considered as a model of PHTG and a mono- . We have elucidated the possible molecular mechanisms responsible for the reduced production of ApoB-48-containing lipoproteins in intestinal epithelial cells. Because of the lack of hepatic NPC1L1 expression in mice 20) , the usage of mice has an advantage to understanding the physiological mechanisms of lipid metabolism in the small intestines as a main target of ezetimibe, contrary to human subjects in which NPC1L1 is believed to be expressed in both small intestines and the liver. Ezetimibe is a strong inhibitor of cholesterol absorption via NPC1L1, and thus cholesterol incorporation into the CM synthesized in the small intestines is reduced by ezetimibe treatment. Therefore, the reduction of cholesterol content in CM and CM remnants may result in a decreased cholesterol pool in the liver, leading to the enhancement of hepatic LDL receptor. Thus, ezetimibe treatment may enhance the catabolism of LDL via hepatic LDL receptor, resulting in the reduction of LDL-cholesterol and possibly CM remnants. Furthermore, reduced cholesterol absorption may lead to the loss of the substrate for CM formation and thereby to attenuation of CM synthesis in the small intestines.
We found that, in both groups, WT mice fed a high fat diet and CD36KO mice fed a chow diet, ezetimibe did not reduce plasma cholesterol concentrations significantly in the fasting state (Fig. 1B) ; however, there remained a small, non-significant tendency for the cholesterol content in plasma to fall in both groups. This might be associated with increased endogenous production of cholesterol in both the intestine and liver in both models, possibly through an increased expression of HMG-CoA synthase, which should be further considered.
We also found that in WT mice fed a chow diet, ezetimibe did not decrease postprandial TG levels (Fig. 1A) ; however, when WT mice were fed a highfat, high-cholesterol diet, ezetimibe reduced the PHTG to normal levels. This might suggest that ezetimibe could reduce postprandial triglyceride levels in We performed qRT-PCR using total mRNA isolated from intestines, and examined the expression of genes associated with FA transport, TG formation and CM assembly for CD36KO (A) and found that ezetimibe administration significantly inhibited the expression of FATP4, apoB and apobec1. In WT mice (B) ezetimibe decreased the expression of FATP4, FABP2, DGAT1, DGAT2, SCD1, apoB and ACF significantly. There was also the upregulation of FAS and ACAT2, which could correspond to a compensatory response. In both cases, ezetimibe decreased the expression of genes involved in FA metabolism and CM production. In a previous publication, our group found that CD36KO mice have an increased TG response to acute fat loads in both plasma and lymph 11) . In the current study, we found that CD36KO showed a higher TG concentration than WT mice even in a high fat loading state in intestinal lymph (Fig. 3) ; this might suggest the hypothesis that CD36KO mice would have a larger CM than WT mice. However, since the CM fraction in our HPLC method was included in the void volume, we could not determine the specific size of individual particles in this fraction, which is considered a whole group, and therefore, we were not able to confirm whether there was really a difference in particle size between these two groups.
The reduced absorption of long-chain FAs observed in this study was in part associated with an inhibitory effect on FATP4 in CD36KO mice as well as the reduction of both FATP4 and FABP2 intestinal expression in WT mice. FATP4 is the only FATP expressed in the intestines 21) , is located in the ER of the intestinal cells and has demonstrated acyl-CoA synthetase activity, which decreases the intracellular concentration of FAs, and would indirectly increase FA uptake when the extracellular concentration is high enough, as in the postprandial state 22) . FATP4 has also been associated with obesity and the insulinresistant state 23) . Labonté et al. 24) reported a reduction of the FATP4 amount in the intestines of both WT mice receiving ezetimibe and NPC1L1 knockout mice compared to WT controls. Although we did not measure the amount of FATP4 protein by Western blotting, we found a decrease in the mRNA content in both treated groups, suggesting inhibition of the regulation of FATP4 at the transcriptional level, which would lead to a decreased amount of FATP4. Taken together, these findings suggest a close relationship between the presence of active NPC1L1 and the uptake, intracellular transport and esterification of long-chain FAs.
In the current study, we also found that WT mice fed a western diet under ezetimibe treatment showed a reduced expression of DGAT1 and DGAT2, two proteins involved in TG synthesis, located in the ER 25) , as well as a decreased expression of SCD1, which is an important lipogenic factor associated with dietary saturated fat-related obesity 26) . SCD1 has been reported to colocalize and interact with DGAT2 27) , suggesting a mechanism of the incorporation of endogenously synthesized FAs into TG. Therefore, ezetimibe might also decrease PHTG in WT mice fed a western diet by reducing the formation of TG in intestinal cells.
Interestingly, in CD36KO mice, ezetimibe administration inhibited only FATP4 expression in the steps prior to CM assembly to reduce PHTG, but not FABP2, nor any of the proteins involved in TG production, as in WT mice, which might suggest that FATP4 could play an essential role in FA metabolism in the CD36KO model, different from WT mice, which also supports the idea that intestinal lipid metabolism in CD36KO mice is different from in WT mice.
On the other hand, we found that ezetimibe administration reduced ApoB mRNA in both treated groups, and moreover, ezetimibe decreased the mRNA levels of apobec1 in CD36KO mice and Apobec1 complementary factor (ACF) in WT mice. Whether ezetimibe decreased ApoB48 mass in lymph only by inhibiting the transcription or by enhancing the posttranscriptional degradation of ApoB is not known yet, and further examination will be required to gain a better understanding of intestinal ApoB metabolism.
Apobec1 is the catalytic subunit of the ApoB editing complex; in the absence of apobec1, there is no ApoB mRNA edition; apobec1 KO mice lack ApoB48, and the only ApoB found in this model is ApoB100 28) . In our study, ezetimibe decreased apobec1 mRNA significantly in CD36KO mice; however, we did not find any traces of ApoB100 in the intestinal lymph collected; therefore, we presume that ApoB mRNA edition was not so low as to make the enterocytes produce ApoB100-containing lipoproteins, but decreased enough to reduce the production of ApoB48 which, in addition to the presence of low TG as a substrate, led to reduced CM production.
Apobec1 complementary factor (ACF), the RNAbinding subunit of the editing complex, interacts with both apobec1 and ApoB mRNA, positioning the ApoB mRNA structure in the optimal configuration to expose the C residue to apobec1, and it has been proposed to be responsible for the specificity of the reaction 29) , and a stabilizer for apobec1 30) . It has been proposed that ACF plays a pivotal role independent of apobec1, since attempts to generate ACF KO mice were not successful beyond the blastocyst state, and siRNA knockdown of ACF in rat and human cells induced an increase in apoptosis. In heterozygote ACF KO mice, ACF protein was found to be decreased in the small intestines; however, intestinal ApoB mRNA edition was not compromised 31) . From this evidence, we could not draw the conclusion that the lowering effect of ezetimibe on the expression of ACF would be actually relevant to ApoB mRNA edition and the production of CM in WT mice.
We have summarized in Fig. 6 the possible mechanisms for the inhibitory effect of ezetimibe treatment on postprandial hypertriglyceridemia. The administration of ezetimibe alone reduces PHTG by inhibiting cholesterol absorption and the expression of genes involved in the uptake, intracellular trafficking and the metabolism of long-chain FAs (FATP4 in both WT and CD36KO mice and FABP2 in WT mice only), as well as by decreasing the formation of TG (SCD1, DGAT1 and DGAT2 in WT mice) and the expression of ApoB (both WT and CD36KO mice) necessary for the production of ApoB48-containing lipoproteins in the small intestine. Furthermore, reduced cholesterol influx to the liver may lead to the up-regulation of hepatic LDL receptor, resulting in the enhanced catabolism of LDL and CM remnants.
In conclusion, ezetimibe alone reduces PHTG in mouse models of MetS by inhibiting cholesterol absorption and uptake, intracellular trafficking and the metabolism of long-chain FAs, as well as decreasing the formation of TG and the expression of apoB, necessary for the production of apoB48-containing lipoproteins in the small intestine. Thus, ezetimibe strongly attenuates the intestinal production of CM, resulting in the inhibition of PHTG, which may eventually lead to the reduction of atherosclerosis in both animal models and humans. Administration of ezetimibe alone reduces PHTG by inhibiting cholesterol absorption and the expression of genes involved in the uptake, intracellular trafficking and metabolism of long-chain FAs (FATP4 in both WT and CD36KO mice and FABP2 in WT mice only), as well as by decreasing the formation of TG (SCD1, DGAT1 and DGAT2 in WT mice) and the expression of apoB (both WT and CD36KO mice), necessary for the production of ApoB48-containing lipoproteins in the small intestine. Furthermore, reduced cholesterol influx to the liver may lead to the up-regulation of hepatic LDL receptor, resulting in the enhanced catabolism of LDL and CM remnants. 
